Thursday, Aug 13, 2020 | Last Update : 03:53 AM IST

140th Day Of Lockdown

Maharashtra53560136843518306 Tamil Nadu3086492506805159 Andhra Pradesh2445491547492203 Karnataka1886111055993398 Delhi1461341316574131 Uttar Pradesh126722767212120 West Bengal98459671202059 Bihar8274154139450 Telangana8075157586637 Gujarat71064542382652 Assam5883842326145 Rajasthan5249738235789 Odisha4592731785321 Haryana4163534781483 Madhya Pradesh3902529020996 Kerala3433121832109 Jammu and Kashmir2489717003472 Punjab2390315319586 Jharkhand185168998177 Chhatisgarh12148880996 Uttarakhand96326134125 Goa871259575 Tripura6161417641 Puducherry5382320187 Manipur3752204411 Himachal Pradesh3371218114 Nagaland30119738 Arunachal Pradesh223115923 Chandigarh1595100425 Meghalaya11154986 Sikkim9105101 Mizoram6203230
  Business   Companies  30 Jun 2020  Bharat Biotech’s COVID-19 vaccine gets nod for human trials

Bharat Biotech’s COVID-19 vaccine gets nod for human trials

REUTERS
Published : Jun 30, 2020, 4:12 pm IST
Updated : Jun 30, 2020, 4:12 pm IST

Human trials are scheduled to start across the country in July, developed and manufactured in Bharat Biotech’s facility in Hyderabad

 India's first COVID-19 vaccine gets nod for human trials. (AFP Photo)
  India's first COVID-19 vaccine gets nod for human trials. (AFP Photo)

Bharat Biotech’s COVID-19 vaccine has been approved for human trials, making it India’s first domestic candidate to get the green light from the government’s drug regulator as cases surge in a country with more than 1.3 billion people.

The Drug Controller General of India has approved the company’s application to conduct a Phase I and II clinical trial of Covaxin, which was developed along with the Indian Council of Medical Research’s National Institute of Virology, the company said in a statement on Monday.

 

Human clinical trials are scheduled to start across the country in July for the vaccine, which was developed and manufactured in Bharat Biotech’s facility at Genome Valley in Hyderabad, India.

India, which lags only the United States, Brazil and Russia in total cases, reported close to 20,000 new infections on Monday, according to data from the country’s federal Health Ministry.

More than 16,000 people have died from the disease since the first case in India in January — low when compared to countries with similar numbers of cases. But experts fear hospitals in the densely populated nation will be unable to cope with a steep rise in cases.

 

Tags: bharat biotech, covid-19 vaccine, human trials, drug regulator, coronavirus cases